Head-to-head evidence
DA-302168S vs TE-8105
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
DA-302168S
Developed by Chendu DIAO Pharmaceutical Group
NCT06953063 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 250 participants, with percentage change in body weight as a clinical primary endpoint. However, results are not posted, so it is not possible to determine whether the primary comparison was met; the available evidence therefore supports a moderate grade rather than a strong one.
Next expected readout: July 2027 · NCT07629544 (registry estimate)
TE-8105
Developed by Immunwork
NCT06471530 · Phase 1/2 · completed
This was an open-label, non-randomized, dose-escalation study with no placebo or control group, so it cannot show whether any effect is attributable to the drug itself. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-302168S's landscape · TE-8105's landscape